Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15705MR)

This product GTTS-WQ15705MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Macular edema following Central Retinal Vein Occlusion (CRVO), Diabetic retinopathy research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ15705MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5058MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CaCP-29
GTTS-WQ9396MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Iomab-B
GTTS-WQ7964MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GX-17
GTTS-WQ4153MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BI-754091
GTTS-WQ1957MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AGS-15E
GTTS-WQ6901MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ9499MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA J2898A
GTTS-WQ13486MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRTX-100
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW